Compare SUPX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPX | TLSI |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 250.0M |
| IPO Year | 2021 | 2020 |
| Metric | SUPX | TLSI |
|---|---|---|
| Price | $5.23 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 254.5K | 192.8K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $14.10 |
| Revenue Next Year | N/A | $37.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $4.11 | $2.20 |
| 52 Week High | $49.99 | $7.95 |
| Indicator | SUPX | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 23.71 |
| Support Level | $4.11 | $2.20 |
| Resistance Level | $7.40 | $4.35 |
| Average True Range (ATR) | 0.60 | 0.31 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 46.12 | 6.72 |
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.